English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 4 January 2022, 10:10 HKT/SGT
Share:
    

Source: Apollomics, Inc.
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group

Foster City, CA, and Hangzhou, China, Jan 4, 2022 - (ACN Newswire) - Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer of Apollomics, was recently appointed to Chairman of the Board for the BayHelix Group, effective January 2022.

"I am honored to be selected by my peers to help guide the BayHelix Group as it continues to foster biotech innovations and expand business opportunities within the broad life sciences ecosystem globally," said Dr. Yu. "For 20 years, the BayHelix group has been an instrumental connection between emerging Chinese companies and the rest of the world. As a dual U.S. and China biotechnology company focused on the development of innovative therapies for cancer treatment, Apollomics has been actively involved with BayHelix since our inception. I look forward to offering my expertise and insights, and working with my distinguished BayHelix board of directors and fellow members, to further our goals towards connecting biopharmaceutical companies around the world."

About BayHelix Group

The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix aspires to foster and create business opportunities, supply and nurture leaders for the community, and network and share information and experience among its members. The diverse membership base covers many of the world's top pharmaceutical and biopharmaceutical companies, leading professional services and investment firms, as well as start-up biotech companies in China and the US. BayHelix membership is by-invitation only. Over two thirds of members are C-level executives. The majority of them are cross trained in science and business as well as bilingual in Chinese and English. BayHelix has become an influential organization that connects emerging biopharmaceutical companies in China to their counterparts around the world.

About Apollomics Inc.

Apollomics Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting and immuno-oncology agents. The Company's product pipeline has several programs at different stages of development, including novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Apollomics has operating entities in Foster City, California, USA, Hangzhou and Shanghai, China. For more information, please visit www.apollomicsinc.com.

Contact Information:

Investor Contact:
Wilson W. Cheung
Chief Financial Officer
(650) 209-4436
wcheung@apollomicsinc.com

U.S. Media Contact:
Remy Bernarda
Corporate Communications
(415) 203-6386
remy.bernarda@apollomicsinc.com

China Media Contact:
Porda Havas International Finance Communications Group
Kelly Fung
General Manager
(852) 3150 6763
kelly.fung@pordahavas.com


Topic: Press release summary
Source: Apollomics, Inc.

Sectors: BioTech, Clinical Trials
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Apollomics, Inc. Related News
Jan 3, 2024 20:10 HKT/SGT
冠科美博在中国完成复发或难治性急性髓细胞白血病uproleselan药物的三期临床桥接研究入组
Jan 3, 2024 20:09 HKT/SGT
冠科美博在中國完成復發或難治性急性髓細胞白血病uproleselan藥物的三期臨床橋接研究入組
Mar 30, 2023 20:31 HKT/SGT
冠科美博(Apollomics Inc.)宣布完成和SPAC Maxpro合并,并在纳斯达克上市
Mar 30, 2023 20:30 HKT/SGT
冠科美博(Apollomics Inc.)宣佈完成和SPAC Maxpro合併,並在納斯達克上市
Mar 30, 2023 20:29 HKT/SGT
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575